Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

579521

registered interest
date	09/09/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Idiopathic Pulmonary Fibrosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much his Department has spent on funding research into improving the treatment of idiopathic pulmonary fibrosis.
tabling member constituency	Erewash
tabling member printed	Maggie Throup
uin	45785
answer	answer is ministerial correction date of answer 14/09/2016 answer text <p>The information requested is not available.</p><p> </p><p>The Department’s National Institute for Health Research (NIHR) spent £25.5 million on respiratory disease research in 2014/15 (the latest available figure). Most of this investment (£16.6 million in 2014/15) is in infrastructure for respiratory research where spend on specific topics such as the treatment of idiopathic pulmonary fibrosis cannot be separated from total infrastructure expenditure. This infrastructure includes NIHR biomedical research centres and the NIHR Clinical Research Network.</p><p> </p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which is funded by the Medical Research Council and NIHR. The programme is currently funding a £1.4 million efficacy and mechanism evaluation of treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole.</p><p><strong> </strong></p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 14/09/2016 16:50:21 answering member 1542 label Biography information for Philip Dunne
tabling member	4447 label Biography information for Maggie Throup

513019

registered interest
date	14/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, which areas have been chosen as test sites for the pre-exposure drug prophyaxis (PrEP); what selection criteria have been used to identify those test sites; and what measures his Department plans to use to assess the effectiveness of PrEP in the test sites over the next two years.
tabling member constituency	Erewash
tabling member printed	Maggie Throup
uin	34127
answer	answer is ministerial correction date of answer 22/04/2016 answer text <p>The planning of the process to select test sites, including timing and criteria for selection, will continue alongside NHS England’s review of its position on the commissioning of pre-exposure prophyaxis (PrEP).</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 22/04/2016 13:06:13 answering member 3918 label Biography information for Jane Ellison
tabling member	4447 label Biography information for Maggie Throup